Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Gets $15M Credit Facility to Fund Cancer Monitoring Tech Development, Commercialization

NEW YORK (GenomeWeb) – Trovagene has secured a $15 million unrestricted debt facility from Silicon Valley Bank and Oxford Finance, the company said on Tuesday.

The San Diego-based firm will use the capital to support development and commercialization of its urine-based cell-free oncogene mutation cancer monitoring technology.

Trovagene said it expects to report holding roughly $35 million in cash and cash equivalents for the second fiscal quarter, which ended on June 30. It reported $22.9 million in cash holdings at the end of the first quarter.

"We continue to advance our proprietary cancer monitoring platform and the application of our technology in clinical settings," Trovagene CFO Stephen Zaniboni said in a statement. "Recent progress includes clinical study results presented at ASCO 2014 and a reference in clinical consensus guidelines for the treatment of certain histiocytic disorders associated with BRAF V600E mutations."

Earlier this week, Trovagene said it partnered with Northwestern University's Robert H. Lurie Comprehensive Care Center and Northwestern Medicine Developmental Therapeutics Institute to assess the clinical utility of its oncogene-based disease management technology for monitoring patients during treatment and to measure outcomes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.